Status:

COMPLETED

Communication Bridge 2

Lead Sponsor:

University of Chicago

Collaborating Sponsors:

National Institute on Aging (NIA)

Conditions:

Primary Progressive Aphasia

Eligibility:

All Genders

18-100 years

Phase:

NA

Brief Summary

This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild Primary Progressive Aphasia (PPA). The aim of the study is to help...

Eligibility Criteria

Inclusion

  • Inclusion Criteria (person with PPA):
  • Meets diagnostic criteria for PPA based on neurologist and supporting medical assessments (extracted from medical records)
  • English as primary language used in daily communication activities (by self-report)
  • Adequate hearing (aided or unaided) for communicating with others in a crowded room (by self-report)
  • Adequate vision (aided or unaided) for reading a newspaper, or other functional materials (by self-report)
  • Able to pass technology screening and demonstrates sufficient knowledge for use of video conference and Communication Bridge™ web application use (with or without training)
  • Geriatric Depression Scale score ≤ 9
  • Mild-moderate PPA informed by a structured interview with a speech-language pathologist and a standardized testing battery.
  • Inclusion Criteria (Co-enrolled communication partner):
  • 18+ years of age
  • English as primary language used in daily communication activities (by self-report)
  • Adequate hearing (aided or unaided) for communicating with others in a crowded room (by self-report)
  • Able to pass technology screening\* and demonstrates sufficient knowledge for use of video conference and Communication Bridge™ web application use (with or without training)
  • Exclusion Criteria:
  • A dementia diagnosis other than Primary Progressive Aphasia
  • Participation is co-enrolled in an outside speech language therapy program during the study course.
  • Communication partners will be excluded if they have a pre-existing communication impairment that would affect study participation (e.g., aphasia, dementia)
  • Medical records will be requested and reviewed to determine eligibility.

Exclusion

    Key Trial Info

    Start Date :

    April 3 2018

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    March 23 2023

    Estimated Enrollment :

    190 Patients enrolled

    Trial Details

    Trial ID

    NCT03371706

    Start Date

    April 3 2018

    End Date

    March 23 2023

    Last Update

    October 17 2024

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    The Healthy Aging & Alzheimer's Research Care Center (University of Chicago)

    Chicago, Illinois, United States, 60637

    Communication Bridge 2 | DecenTrialz